london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Intravitreal anti-VEGF therapy for choroidal neovascularization secondary to pathologic myopia- 6 year outcome

Session Details

Session Title: FP-15 Vascular Diseases and Diabetic Retinopathy V

Session Date/Time: Sunday 14/09/2014 | 08:00-10:00

Paper Time: 08:00

Venue: Boulevard D

First Author: : J.M.Ruiz-Moreno SPAIN

Co Author(s): :    J. Araiz   L. Arias   J. Montero   A. García-Layana   M. Figueroa   R. Silva

Abstract Details

Purpose:

To report the visual outcome after six-year follow-up in highly myopic eyes with choroidal neovascularization (CNV) treated with anti-vascular endothelial growth factor (VEGF) drugs.

Setting:

Multicentric study

Methods:

Retrospective, non-randomized, multicenter, consecutive, interventional case series study. 130 highly myopic eyes with subfoveal CNV were treated with intravitreal injections (IVI) of anti-VEGF. The initial protocol (one vs. three injections) and drug (bevacizumab/ranibizumab) were dictated by surgeons’ preferences and followed by a PRN monthly regime. Best-corrected visual acuity (BCVA) was evaluated at baseline and then monthly. The primary aim was to analyze BCVA changes. The effect of age, spherical equivalent, treating drug, and initial protocol, diameter of CNV and BCVA were evaluated as secondary objectives

Results:

Mean age of the patients was 56.5 years (standard deviation (SD) 12.7, range 31 to 90). Average number of letters read at baseline was 55.3 (SD 17.8; 5 to 85); 63.3 (SD 18.2; 5 to 85) at 12 months; 61.6 (SD 20.2; 5 to 90) at 24 months; 61.0 (SD 20.2; 2 to 90) at 36 months; 59.6 (SD 20.8; 5 to 90) at 48 months; 57.0 (SD 22.5; 5 to 89) at 60 months and 56.5 (SD 24.5; 5 to 95) at 72 months (p=0.000, between initial vs. 12, 24 and 36 months; p=0.01, 0.3 and 0.8 between initial vs. 48, 60 and 72 months respectively; Student’s t test paired data). The mean total number of IVI was 4.0 (SD 5.4; range 1 to 24). 51 eyes no needed retreatment after initial protocol. Age, initial BCVA and re-treatments required are correlated with visual outcome

Conclusions:

Bevacizumab and ranibizumab are effective therapies and show similar clinical effects in highly myopic CNV. Visual acuity gain is maintained in a 4-year follow-up. In five and six years the improvement is not statistically significant

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy